| Literature DB >> 32090200 |
Hayley J MacDonald1,2, John-Stuart Brittain2,3, Bernhard Spitzer4, Simon Hanslmayr2,3, Ned Jenkinson1,2.
Abstract
There is an increasing recognition of the significant non-motor symptoms that burden people with Parkinson's disease. As such, there is a pressing need to better understand and investigate the mechanisms underpinning these non-motor deficits. The electrical activity within the brains of people with Parkinson's disease is known to exhibit excessive power within the beta range (12-30 Hz), compared with healthy controls. The weight of evidence suggests that this abnormally high level of beta power is the cause of bradykinesia and rigidity in Parkinson's disease. However, less is known about how the abnormal beta rhythms seen in Parkinson's disease impact on non-motor symptoms. In healthy adults, beta power decreases are necessary for successful episodic memory formation, with greater power decreases during the encoding phase predicting which words will subsequently be remembered. Given the raised levels of beta activity in people with Parkinson's disease, we hypothesized that the necessary decrease in power during memory encoding would be diminished and that this would interfere with episodic memory formation. Accordingly, we conducted a cross-sectional, laboratory-based experimental study to investigate whether there was a direct relationship between decreased beta modulation and memory formation in Parkinson's disease. Electroencephalography recordings were made during an established memory-encoding paradigm to examine brain activity in a cohort of adults with Parkinson's disease (N = 28, 20 males) and age-matched controls (N = 31, 18 males). The participants with Parkinson's disease were aged 65 ± 6 years, with an average disease duration of 6 ± 4 years, and tested on their normal medications to avoid the confound of exacerbated motor symptoms. Parkinson's disease participants showed impaired memory strength (P = 0.023) and reduced beta power decreases (P = 0.014) relative to controls. Longer disease duration was correlated with a larger reduction in beta modulation during encoding, and a concomitant reduction in memory performance. The inability to sufficiently decrease beta activity during semantic processing makes it a likely candidate to be the central neural mechanism underlying this type of memory deficit in Parkinson's disease. These novel results extend the notion that pathological beta activity is causally implicated in the motor and (lesser appreciated) non-motor deficits inherent to Parkinson's disease. These findings provide important empirical evidence that should be considered in the development of intelligent next-generation therapies.Entities:
Keywords: Parkinson’s disease; beta oscillations; episodic memory; semantic encoding
Year: 2019 PMID: 32090200 PMCID: PMC7025167 DOI: 10.1093/braincomms/fcz040
Source DB: PubMed Journal: Brain Commun ISSN: 2632-1297
Figure 1Three stages of memory task. The letters in brackets indicated to participants that button on the keyboard corresponded to which response. In the final screen for a recognition trial, participants saw assigned responses (i.e. recollection, very familiar, etc.) rather than R1–R6, which are shown here due to space constraints.
Figure 2Receiver operating characteristic curves for a representative control. (A) and Parkinson’s disease participant (B) in deep-semantic- and shallow-non-semantic-encoding conditions. The false alarm rate is cumulative. The responses given on the 6-point rating scale are grouped into the following conditions: HH, LH and M.
Participant demographics and global cognitive function
| HC | Parkinson’s disease | |
|---|---|---|
| Age (years) | 67 (9) | 65 (6) |
| Education | 3.8 (0.4) | 3.9 (0.4) |
| Gender | 13F/18M | 8F/20M |
| Disease duration (years) | N/A | 6 (4) |
| Handedness | 3L/28R | 5L/23R |
| OCS-Plus | 9.7 (0.5) | 9.7 (0.5) |
Values are mean (SD) unless otherwise specified. F = female; HC = healthy controls; M = male; OCS-Plus = Oxford Cognitive Screen Plus questionnaire (maximum 10); L = left-handed; R = right-handed; N/A = not applicable. Education is grouped into 1 = no formal education; 2 = primary school; 3 = secondary school; and 4 = tertiary level.
Demographic and clinical data for Parkinson’s participants
| Subject | Age (years) | Gender | Parkinson’s disease medication | LEDD (mg) | Disease duration (years) | Side most affected |
|---|---|---|---|---|---|---|
| 1 | 61 | M |
Stalevo: 375 mg levodopa (5 × 75 mg/18.75 mg/200 mg) Ropinirole 8 mg Rasagiline 1 mg | 759 | 11 | R |
| 2 | 65 | F |
Rasagiline 1 mg Madopar: 800 mg levodopa (4 × 50 mg/200 mg) | 900 | 8 | L |
| 3 | 76 | F |
Repinex 8 mg Sinemet: 500 mg levodopa (4 × 25 mg/100 mg, 1 × 25 mg/100 mg CR) | 635 | 11 | L |
| 4 | 68 | M | Sinemet: 300 mg levodopa (3 × 25 mg/100 mg) | 300 | 5 | R |
| 5 | 62 | M |
Stalevo: 200 mg levodopa (4 × 50 mg/12.5 mg/200 mg) Rasagiline 1 mg Apomorphine 3 mg Repinex 4 mg | 476 | 10 | R |
| 6 | 67 | M |
Madopar: 200 mg levodopa (4 × 12.5 mg/50 mg) Rasagiline 1 mg | 300 | 2 | L |
| 7 | 68 | M |
Madopar: 400 mg levodopa (4 × 25 mg/100 mg) Rasagiline 1 mg Repinex 8 mg | 660 | 8 | L |
| 8 | 58 | F |
Madopar: 300 mg levodopa (3 × 25 mg/100 mg) Mirapexin 0.26 mg | 326 | 6 | L |
| 9 | 72 | M |
Selegiline 5 mg Sinemet: 500 mg levodopa (5 × 25 mg/100 mg) ReQuipXL 12 mg Amantadine 300 mg | 1090 | 13 | L |
| 10 | 79 | M |
Rasagiline 1 mg Ropinirole 8 mg | 260 | 6 | R |
| 11 | 74 | M |
Stalevo: 700 mg levodopa (3 × 200 mg/50 mg/200 mg, 1 × 100 mg/25 mg/200 mg) Amantadine 300 mg Rotigotine 16 mg | 1711 | 14 | L |
| 12 | 64 | M | Mirapexin 1.56 mg | 156 | 3 | L |
| 13 | 67 | M |
Rotigotine 8 mg Rasagiline 1 mg Madopar: 400 mg levodopa (4 × 25 mg/100 mg) Entacapone 800 mg | 1804 | 10 | R |
| 14 | 67 | M |
Rasagiline 1 mg Pramipexole 2.1 mg Sinemet: 300 mg levodopa (3 × 25 mg/100 mg) | 610 | 4 | R |
| 15 | 61 | F | None | N/A | 3 | L |
| 16 | 59 | M | Rasagiline 1 mg | 100 | 1 | R |
| 17 | 56 | F |
Rasagiline 1 mg Sinemet: 100 mg levodopa (1 × 25 mg/100 mg) Stalevo: 250 mg levodopa (3 × 50 mg/12.5 mg/200 mg 1 × 100 mg/25 mg/200 mg) Ropinirole 12 mg | 773 | 5 | L |
| 18 | 75 | M | Rotigotine 6 mgMadopar: 500 mg levodopa (5 × 25 mg/100 mg) | 680 | 3 | L |
| 19 | 62 | F | Sinemet: 150 mg levodopa (3 × 12.5 mg/50 mg) | 150 | 0.33 | L |
| 20 | 58 | M | Sinemet: 150 mg levodopa (3 × 12.5 mg/50 mg) | 150 | 1 | L |
| 21 | 70 | M | Sinemet: 400 mg levodopa (4 × 25 mg/100 mg) | 400 | 4 | L |
| 22 | 59 | F |
Ropinirole 12 mg Sinemet: 400 mg levodopa (4 × 25 mg/100 mg) | 640 | 7 | L |
| 23 | 69 | M | Madopar: 150 mg levodopa (3 × 12.5 mg/50 mg) | 150 | 0.5 | L |
| 24 | 62 | M |
Madopar: 700 mg levodopa (6 × 25 mg/100 mg, 1 × 25 mg/100 mg CR) Ropinirole 16 mg | 1020 | 6 | R |
| 25 | 63 | M | Requip 10 mg | 200 | 1 | L |
| 26 | 61 | F |
Ropinirole 8 mg Madopar: 400 mg levodopa (8 × 12.5 mg/50 mg) | 560 | 4 | L |
| 27 | 54 | M |
Madopar: 400 mg levodopa (4 × 25 mg/100 mg) Selegiline 25 mg | 650 | 1 | L |
| 28 | 73 | M | Sinemet: 400 mg levodopa (4 × 25 mg/100 mg) | 400 | 8 | R |
LEDD = levodopa equivalent daily dose; M = male; F = female; CR = continuous release; L = left; R = right; N/A = not applicable.
Figure 3Memory performance. (A) Memory performance during encoding conditions illustrating greater memory strength during deep-semantic encoding for healthy controls (N = 31) compared with Parkinson’s disease participants (N = 28). Error bars denote standard error of the mean. *P < 0.05. (B) Correlation between deep encoding memory performance and disease duration for Parkinson’s disease participants (P = 0.002).
Figure 4Event-related decreases in beta power. Average beta (12–20 Hz) event-related power decrease for electrodes in significant and/or largest cluster identified during cluster-based statistical analysis. Top row: between-group differences during deep-semantic encoding of remembered words; middle row: between-group differences during shallow-non-semantic encoding of remembered words; bottom row: differences within healthy participants between deep-semantic and shallow-non-semantic encoding of remembered words. Grey dashed squares indicate time window used in statistical analysis to identify significant electrode clusters over 12–20 Hz. Time course of decreases in beta power averaged over electrodes contributing to significant and/or largest cluster during encoding of subsequently successfully remembered words for controls (blue, N = 30) compared with Parkinson’s disease participants (red, N = 26) in the deep-semantic-encoding (A) and shallow-non-semantic-encoding (C) conditions. A power decrease is denoted with negative values. Only deep-semantic encoding showed a significant difference between groups (electrodes contributing to significant cluster black in B). Topographical maps show the location of the differences in beta power decreases between groups in deep (B) and shallow (D) encoding, with colder colours indicating significantly greater decreases in beta power in controls compared with Parkinson’s disease participants. Cluster shown for shallow-non-semantic encoding in C and D did not reach significance. (E) Time course of beta power decrease averaged over electrodes contributing to significant cluster during encoding of subsequently successfully remembered words for deep-semantic (green) compared with shallow-non-semantic encoding (magenta) in controls. A power decrease is denoted with negative values. Only controls showed a significant difference between encoding conditions (electrodes contributing to significant cluster black in F). Topographical map in F shows the location of differences in beta power decreases between encoding conditions, with colder colours indicating significantly greater reductions in beta power in deep-semantic compared with shallow-non-semantic encoding. No cluster identified between encoding conditions for Parkinson’s disease patients.
Figure 5Correlations in Parkinson’s disease patients. (A) Correlation between deep-semantic-encoding memory performance and maximum decrease in beta power over left frontal electrodes for Parkinson’s disease participants (N = 26, P = 0.008, R2 = 0.256). (B) Correlation between maximum decrease in beta power over left frontal electrodes and disease duration for Parkinson’s disease participants (N = 26, P = 0.007).
Figure 6Subsequent-memory effects. Average beta (12–20 Hz) event-related power decreases for electrodes in significant and/or largest cluster identified during cluster-based statistical analysis. Top row: differences within healthy participants between remembered and forgotten words during deep-semantic encoding; second row: differences within Parkinson’s disease participants between remembered and forgotten words during deep-semantic encoding; third row: differences within healthy participants between remembered and forgotten words during shallow-non-semantic encoding; bottom row: differences within Parkinson’s disease participants between remembered and forgotten words during shallow-non-semantic encoding. Grey dashed squares indicate time window used in statistical analysis to identify significant electrode clusters over 12–20 Hz. Time course of decrease in beta power averaged over electrodes contributing to significant and/or largest cluster during Hit (H, cyan) compared with M (yellow) trials in deep encoding for controls (A, N = 27) and Parkinson’s disease participants (C, N = 25). Both groups demonstrated greater reductions in beta power during encoding of subsequently remembered (H) compared with forgotten (M) words, but only the clusters in deep-semantic encoding reached significance (electrodes contributing to significant cluster black in B and D). Topographical maps show the location of differences in beta power decrease between words in deep-semantic encoding for controls (B) and Parkinson’s disease patients (D), with colder colours indicating greater reductions in beta power for remembered compared with forgotten words. Time course and location of decreases in beta power averaged over electrodes contributing to largest, non-significant cluster during H (cyan) compared with M (yellow) trials in shallow-non-semantic encoding for controls (E and F, N = 27) and Parkinson’s disease participants (G and H, N = 25).